Clostridioides difficile Infection in the Stem Cell Transplant and Hematologic Malignancy Population

• Autores: Elizabeth Ann Misch, Nasia Safdar
• Localización: Infectious disease clinics of North America, ISSN 0891-5520, Vol. 33, Nº. 2, 2019 (Ejemplar dedicado a: Management of Infectious Diseases in Stem Cell Transplantation and Hematologic Malignancy), págs. 447-466
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Clostridioides difficile infection (CDI) is common in the stem cell transplant (SCT) and hematologic malignancy (HM) population and mostly occurs in the early posttransplant period. Treatment of CDI in SCT/HM is the same as for the general population, with the exception that fecal microbiota transplant (FMT) has not been widely adopted because of safety concerns. Several case reports, small series, and retrospective studies have shown that FMT is effective and safe. A randomized controlled trial of FMT for prophylaxis of CDI in SCT patients is underway. In addition, an abundance of novel therapeutics for CDI is currently in development.